NASDAQ:ASRT

Assertio (ASRT) Stock Price, News & Analysis

$1.00
+0.08 (+8.45%)
(As of 12:38 PM ET)
Today's Range
$0.94
$1.03
50-Day Range
$0.75
$1.14
52-Week Range
$0.73
$8.01
Volume
712,094 shs
Average Volume
1.02 million shs
Market Capitalization
$95.02 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.50

Assertio MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
461.2% Upside
$5.50 Price Target
Short Interest
Bearish
11.31% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Selling Shares
$11,481 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.04) to $0.19 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.06 out of 5 stars

Medical Sector

762nd out of 924 stocks

Pharmaceutical Preparations Industry

351st out of 427 stocks

ASRT stock logo

About Assertio Stock (NASDAQ:ASRT)

Assertio Holdings, Inc., a commercial pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides Sympazan, a benzodiazepine for the adjunctive treatment of seizures related with lennox-gastaut syndrome in patients aged two years of age or older; CAMBIA, a non steroidal anti inflammatory drug (NSAID) for the treatment of migraine pain, nausea, photophobia, and phonophobia; Zipsor, a NSAID for relief of mild to moderate pain in adults; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat patients with severe, active rheumatoid arthritis, and active polyarticular juvenile idiopathic arthritis, as well as treat adult with severe, recalcitrant, and disabling psoriasis; and ROLVEDON, a long-acting granulocyte colony-stimulating factor that is indicated to decrease the incidence of infection caused by febrile neutropenia. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 2020 and is headquartered in Lake Forest, Illinois.

ASRT Stock Price History

ASRT Stock News Headlines

Sig Kirk Joins Assertio Board of Directors
Gold Mania
Former Goldman VP Reveals Mysterious "Gold Bank" With Huge Upside Potential He says the gains in this should be far greater than just bullion or mining stocks. Some folks had the chance to see 995% the last time we shared this exact "bank". Most people know nothing about it (except the rich and elite).
Q4 2023 Assertio Holdings Inc Earnings Call
Gold Mania
Former Goldman VP Reveals Mysterious "Gold Bank" With Huge Upside Potential He says the gains in this should be far greater than just bullion or mining stocks. Some folks had the chance to see 995% the last time we shared this exact "bank". Most people know nothing about it (except the rich and elite).
Recap: Assertio Holdings Q4 Earnings
Assertio: Q4 Earnings Snapshot
ASRT Mar 2024 4.500 call
Assertio Holdings's Earnings: A Preview
Assertio 24 Hour Deadline Alert
Assertio 48 Hour Deadline Alert
Assertio Shareholder Notice
See More Headlines
Receive ASRT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Assertio and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/11/2024
Today
5/02/2024
Next Earnings (Confirmed)
5/06/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ASRT
Employees
53
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$5.50
High Stock Price Target
$7.00
Low Stock Price Target
$4.00
Potential Upside/Downside
+461.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-331,940,000.00
Net Margins
-218.28%
Pretax Margin
-167.07%

Debt

Sales & Book Value

Annual Sales
$152.07 million
Cash Flow
$0.80 per share
Book Value
$1.46 per share

Miscellaneous

Free Float
92,078,000
Market Cap
$93.22 million
Optionable
Optionable
Beta
1.00
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

ASRT Stock Analysis - Frequently Asked Questions

Should I buy or sell Assertio stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Assertio in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ASRT shares.
View ASRT analyst ratings
or view top-rated stocks.

What is Assertio's stock price target for 2024?

1 brokers have issued 12-month price objectives for Assertio's shares. Their ASRT share price targets range from $4.00 to $7.00. On average, they predict the company's stock price to reach $5.50 in the next twelve months. This suggests a possible upside of 461.2% from the stock's current price.
View analysts price targets for ASRT
or view top-rated stocks among Wall Street analysts.

How have ASRT shares performed in 2024?

Assertio's stock was trading at $1.07 at the beginning of 2024. Since then, ASRT stock has decreased by 8.4% and is now trading at $0.98.
View the best growth stocks for 2024 here
.

When is Assertio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 6th 2024.
View our ASRT earnings forecast
.

How can I listen to Assertio's earnings call?

Assertio will be holding an earnings conference call on Monday, May 6th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

How were Assertio's earnings last quarter?

Assertio Holdings, Inc. (NASDAQ:ASRT) issued its quarterly earnings results on Monday, March, 11th. The company reported $0.08 EPS for the quarter. The business earned $32.99 million during the quarter, compared to the consensus estimate of $31.42 million. Assertio had a negative net margin of 218.28% and a positive trailing twelve-month return on equity of 6.30%.

What guidance has Assertio issued on next quarter's earnings?

Assertio issued an update on its FY 2024 earnings guidance on Tuesday, March, 12th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $110.0 million-$125.0 million, compared to the consensus revenue estimate of $160.6 million.

What other stocks do shareholders of Assertio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Assertio investors own include Sorrento Therapeutics (SRNE), Actinium Pharmaceuticals (ATNM), T2 Biosystems (TTOO), VBI Vaccines (VBIV), InterDigital (IDCC), Trevena (TRVN), Bionano Genomics (BNGO), Cerecor (CERC) and OPKO Health (OPK).

Who are Assertio's major shareholders?

Assertio's stock is owned by a variety of institutional and retail investors. Top institutional investors include TSP Capital Management Group LLC (0.23%), Denali Advisors LLC (0.17%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Ajay Patel, Daniel A Peisert, Heather L Mason, James L Tyree, Paul Schwichtenberg, Sam Schlessinger and William Mckee.
View institutional ownership trends
.

How do I buy shares of Assertio?

Shares of ASRT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ASRT) was last updated on 5/2/2024 by MarketBeat.com Staff

From Our Partners